<DOC>
	<DOC>NCT02181738</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B &amp; C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma subjects.</brief_summary>
	<brief_title>Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Must have received prior highdose conditioning chemotherapy followed by autologous stem cell transplant (ASCT) as a part of salvage therapy for cHL (cohort A, B &amp; C enrolment closed) Subjects may be Brentuximab vedotin naïve, or may have had prior Brentuximab vedotin treatment (cohort A, B &amp; C enrolment closed) Newly diagnosed and previously untreated classical Hodgkin Lymphoma (cohort D) Known central nervous system lymphoma Subjects with nodular lymphocytepredominant Hodgkin Lymphoma Prior allogeneic stem cell transplantation (SCT) Chest radiation ≤ 24 weeks prior to first dose Carmustine ≥ 600 mg/m² received as part of the pretransplant conditioning regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>